Recording Methods and the Capabilities of Modern Respiratory Rate Monitoring Devices (literature review).

Determination of respiratory rate is a necessary task in assessing the state of health in humans. This review provides a description of modern devices used for recording and monitoring respiratory rate. The advantages and disadvantages of the principles of operation of these devices are discussed.

Experimental Study of a Radiopharmaceutical Agent Based on Modified Fatty Acid Labeled with Technetium-99m.

Using rat model of coronary occlusion, we studied pharmacokinetics and the efficiency of a new radiopharmaceutical agent 99mTc-PDA-DTPA intended for diagnostics of changes in myocardial metabolism and its analogue 123I-PMPDA. 99mTc-PDA-DTPA was eliminated mostly by the kidneys and maximal concentration in the heart was attained within 60 min after intravenous injection; no accumulation in the area of myocardial infarction was observed. The studied substance was inferior to its analogue 123I-PMPDA by the quality of scintigraphic visualization of the heart.

Studying the General Toxicity and Cumulative Properties of a Radiopharmaceutical Nanocolloid, (99m)Tc-Al2O3.

We studied toxicity of a new Russian radiopharmaceutical Nanocolloid, (99m)Tc-Al2O3. Tests for acute toxicity showed that this agent belongs to a class of moderate-toxicity substances and does not have cumulative properties. The evaluation of subchronic toxicity after subcutaneous injection of this product to rats (0.04, 0.2, and 0.4 ml/kg) and rabbits (0.02 and 0.2 ml/kg) for 7 days did not reveal changes in the general state, temperature, body weight, indices of the peripheral blood and bone marrow, functions of the heart, liver, kidneys, and nervous system, and morphological characteristics of the internal organs in animals. The drug does not produce a local irritant effect.

[STUDYING ACUTE TOXICITY OF NEW RADIOPHARMACEUTICAL 99MTC-AL2O3 NANOCOLLOIDS FOR ONCOLOGICAL DIAGNOSTICS].

The acute toxicity of a new drug based on nanocolloidal gamma alumina labeled with technetium-99m (99mTc) has been studied on 80 rats (40 females and 40 males) and 80 mice (40 females and 40 males) with intraperitoneal and subcutaneous drug administration. A single administration of the pharmacological agent was followed by observation of the survival of animals for 14 days with determining tolerable, toxic, and lethal doses for intraperitoneal and subcutaneous administration according to the Litchfield - Wilcoxon method, establishing the causes of animal death within 14 days of observation, and studying the drug influence on the general condition and some functional and morphological indices. Based on the established boundaries of toxicity and the classification of toxicity, the 99mTc-Al2O3 nanocolloids can be classified into conditionally moderately toxic substances. The actual values of LD5 of the radiopharmaceutical fall in the range of large doses. The safety factor for the drug studied significantly exceeds the minimum permissible value of 100.

Analysis of mechanisms of interaction between ciprofloxacin-based radiopharmaceutical labeled with technetium-99m and cultured Staphylococcus aureus.

Mechanisms of interaction between ciprofloxacin-based radiopharmaceutical labeled with technetium-99m and cultured Staphylococcus aureus were studied. The substance, reagent for radiopharmaceutical, and the radiopharmaceutical demonstrated similar bactericidal activity against the test bacterial cultures, which confirmed specific antibacterial activity of technetium-99m-labeled ciprofloxacin. The technetium-99m-labeled antibiotic reversibly interacts with inactivated Staphylococcus aureus culture, which indicates the existence of an additional non-specific pathway for radiopharmaceutical accumulation in the bacterial inflammation focus. Our experiment ruled out the possibility of binding free technetium-99m at concentrations <5% (its concentration in the radiopharmaceutical) with Staphylococcus aureus.